ReviewMolecular therapy. Nucleic acids2026
Insights into extracellular vesicles: From biogenesis and tumor immune modulation to their clinical potential in immunotherapy.
Review in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) constitute a key mode of intercellular communication that remodels the complex tumor immune microenvironment by delivering diverse bioactive cargoes between tumor and immune cells. Nucleic acid species, encompassing microRNAs (miRNAs), messenger RNA (mRNAs), and other RNA transcripts, are functionally potent EV cargoes whose selective packaging dictates downstream immune signaling output. This review describes the molecular mechanisms driving selective RNA sorting into EVs, emphasizing sequence-motif recognition and core RNA-binding proteins FMR1 and TRIM25, which govern the enrichment of distinct RNA populations. We illustrate how EV-shuttled RNA molecules elicit context-dependent functional changes across regulatory T cells, myeloid-derived suppressor cells, and macrophages to shape antitumor or pro-tumor immune states. It critically integrates liquid biopsy evidence for EV-borne RNAs and EV-associated programmed death-ligand 1 (PD-L1) as predictive biomarkers of immunotherapy response in melanoma, non-small cell lung cancer, and hepatocellular carcinoma and dissects technical confounders such as non-vesicular RNA contamination and inconsistent isolation protocols. This review further compares nucleic acid loading strategies for native EVs versus cell-membrane-mimetic nanovesicles and explores their applicability for mRNA-based nanovaccines and combinatorial immunotherapy. We highlight underappreciated translational obstacles, noting that harmonized analytical standards, strict encapsulated cargo validation, and independent prospective multicenter trials are essential to translate EV-nucleic acid signatures into personalized cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.